Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672984 | 0.81 | PTGS2 (0.50) | NPC1RAB9AKMT2AHTR2A | |
| SCHEMBL11550836 | 0.80 | NPC1 (0.49) | SRD5A2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2763483 | 0.79 | NPC1 (0.45) | SRD5A2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL22462251 | 0.78 | NPC1 (0.47) | SRD5A2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2923177 | 0.78 | MGLL (0.56) | NPC1RAB9AMEN1KMT2ACYP2D6 | |
| SCHEMBL2743573 | 0.77 | SRD5A2 (0.71) | SRD5A2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2763268 | 0.76 | NPC1 (0.43) | SRD5A2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL271988 | 0.76 | SRC (0.78) | SRCMEN1KMT2ACYP2D6HTR2A | |
| SCHEMBL3750287 | 0.76 | NPC1 (0.49) | SRD5A2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14312085 | 0.75 | SRD5A2 (0.54) | SRD5A2KMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1091938-B1 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | AVENTISUB II INC (US) | 2010-10-20 | — | — | EP | claimed |
| US-6930197-B2 | Antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2005-08-16 | — | — | US | claimed |
| US-6730791-B2 | FOR THERAPY OF ALLERGIES | AVENTIS PHARMACEUTICALS INC. | 2004-05-04 | — | — | US | claimed |
| US-20020111513-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-08-15 | — | — | US | claimed |
| US-20020099088-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | claimed |
| EP-1091938-A2 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | Aventis Pharmaceuticals Inc. (US) | 2001-04-18 | — | — | EP | claimed |
| WO-2000001671-A2 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2000-01-13 | — | — | WO | claimed |
| EP-1091938-B1 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | AVENTISUB II INC (US) | 2010-10-20 | — | — | EP | disclosed |
| US-6930197-B2 | Antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2005-08-16 | — | — | US | disclosed |
| US-6730791-B2 | FOR THERAPY OF ALLERGIES | AVENTIS PHARMACEUTICALS INC. | 2004-05-04 | — | — | US | disclosed |
| US-6700012-B2 | FOR THERAPY OF ALLERGIC DISORDERS | AVENTIS PHARMACEUTICALS INC. | 2004-03-02 | — | — | US | disclosed |
| US-6689898-B2 | FOR THERAPY OF ALLERGIES | AVENTIS PHARMACEUTICALS INC. | 2004-02-10 | — | — | US | disclosed |
| US-6683094-B2 | 4-(1-HYDROXY-4-(4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINYL)BUTYL) -ALPHA-(HYDROXYMETHYL)-ALPHA-METHYL-BENZENEACETIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. | 2004-01-27 | — | — | US | disclosed |
| US-20020111513-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-08-15 | — | — | US | disclosed |
| US-20020099088-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| US-20020099090-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| US-20020099077-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| US-20020099091-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| EP-1091938-A2 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | Aventis Pharmaceuticals Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001671-A2 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099088-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH2, HRH1, HRH4 | SRC 4795/4885SRD5A2 3735/4885NPC1 1460/4885 |
| US-20020111513-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | SRC 4813/4885SRD5A2 2641/4885NPC1 895/4885 |
| US-20020099077-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | SRC 4589/4885SRD5A2 1683/4885NPC1 708/4885 |
| US-20020099091-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | SRC 4762/4885SRD5A2 2180/4885NPC1 976/4885 |
| US-20020099090-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | SRC 4798/4885SRD5A2 2021/4885NPC1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.